Considering the major clinical challenge represented by the tumor resistance to MDM2 inhibitors, it is reasonable that the next frontier in MDM2 research is to develop efficient inhibitors endowed with potential to modulate p53 downstream signals involved in tumor sensitization beside its intrinsic p53-activation capability. This evidence concerns the gene TP53 and neoplasm.